Kornimate/medical-research-clean huggingface dataset:
troponin- i elevation predicts outcome after thrombolysis in stroke patients

Conditions: Cerebrovascular Accident

Summary: elevated level of serum troponin (t-i) has been regarded as a prognostic biomarker of poor outcome in acute ischemic stroke. however, its role in outcome in thrombolysed ischemic stroke patients remains uncertain. the aim of this study was to evaluate the role of t-i as a predictive biomarker of short-term outcome in thrombolysed ischemic stroke participants.

elevated level of serum troponin (t-i) has been regarded as a prognostic biomarker of poor outcome in acute ischemic stroke. however, its role in outcome in thrombolysed ischemic stroke patients remains uncertain. the aim of this study was to evaluate the role of t-i as a predictive biomarker of short-term outcome in thrombolysed ischemic stroke patients. methods: this study included 72 acute ischemic stroke participants were treated with intravenous thrombolytic therapy. all participants were subjected to general and neurological evaluation including assessment of stroke severity using national institute of health stroke scale (nihss) at admission and investigations including measurement of serum level of t-i on admission. outcome was assessed three months after stroke onset using nihss and modified rankin scale (mrs).

Eligibility criteria:
inclusion criteria: * participants were eligible for inclusion in the study if they had evidence suggesting acute ischemic stroke that lasted for ≤ 4.5 hours . * those participants were treated with intravenous thrombolytic therapy ((recombinant tissue plasminogen activator (rt-pa)). exclusion criteria: * those who had hemorrhagic stroke * participants presented with acute myocardial infarction, cerebrovascular stroke in the previous three months. * serious head trauma in the previous three months. * urinary tract, lung, or gastrointestinal hemorrhage within the three weeks. * serious trauma or major surgery within the previous two weeks. * lumbar or arterial puncture at a non-compressible site within one week. * those received heparin within 48 hours, resulting in an activated partial thromboplastin time greater than the upper limit of normal. * systolic pressure \> 185 mmhg or diastolic pressure \> 110 mmhg. * blood glucose \ 400 mg/dl. * current use of anticoagulants with an international normalized ratio \> 1.7 or prothrombin time\>15 sec; platelet count \< 100,000/mm3. * pregnancy; serious heart, lung, kidney or other organ dysfunction. * allergy to active ingredients of rt-pa; patients with \> 4.5 hours from the last time known to be asymptomatic. * those in whom troponin was not measured at admission were excluded from the study

Keywords: acute ischemic stroke troponin-i outcome intravenous thrombolytic therapy
assessment of left ventricular filling pressure by applying artificial intelligence algorithms to left atrial speckle-tracking echocardiography

Conditions: Heart Failure, Diastolic; Echocardiography

Summary: the goal of this single-center, prospective, observational study is to validate a software package based on an artificial intelligence algorithm for automated non-invasive estimation of lvfp against invasively measured ones by left and right heart catheterization; in addition, the added value of this new automated software to detect increased lvedp \> 15 mm hg compared to the current ase/eacvi algorithm for assessing diastolic dysfunction and longitudinal left atrial strain during the reservoir phase will be evaluated.


Eligibility criteria:
inclusion criteria: * ≥ 18 yo, * signed informed consent to be part of this study, * no pregnancy, * good acoustic window and patient cooperation to obtain good 2- and 3-dimensional datasets focused on left atrium (la), exclusion criteria: * unwillingness to be part of the study, * patients with poor 2-dimensional imaging quality in ≥ 1 la segment or lacking of a discernible r-r interval, which might preclude accurate strain measurements, * patients with more than mild mitral valve heart disease, aortic regurgitation, left side valvular prosthesis or mitral valve repair, mitral annulus calcification (≥ 5 mm), * patients with history or presence of atrial fibrillation (af), supraventricular arrhythmias, ventricular paced rhythm, left bundle branch block (lbbb), * patients taking diuretics or vasodilators (nitrates) on the day of the examination, which could alter loading conditions.

Keywords: transthoracic echocardiography left ventricular filling pressure artificial intelligence right heart catheterization
telmisartan+amlodipine fixed dose combination in hypertension

Conditions: Hypertension

Summary: the primary objectives of this trial is to evaluate the changes from baseline (visit 2) in the 24-hour ambulatory blood pressure monitoring mean (relative to dose time) for diastolic blood pressure and systolic blood pressure after 8 weeks of treatment with telmisartan 80mg/amlodipine 5mg in patients with moderate to severe hypertension


Eligibility criteria:
inclusion criteria: 1. aged at least 18 years at the date of signing the consent form 2. for treatment-naïve patients: hypertension defined by a mean seated diastolic blood pressure (dbp) equal or more than 100 mmhg measured by manual cuff sphygmomanometry at visit 1 and 2; for pretreatment patients: hypertension defined by a mean seated diastolic blood pressure equal or more than 90 mmhg at visit 1 and equal or more than 100 mmhg at visit 2 measured by manual cuff sphygmomanometry 3. 24-hour mean diastolic blood pressure equal or more than 85 mmhg at baseline ambulatory blood pressure monitoring exclusion criteria: 1. mean seated systolic blood pressure equal or more than 200 mmhg and/or mean seated diastolic blood pressure equal or more than 120 mmhg 2. any clinically significant hepatic impairment 3. severe renal impairment 4. bilateral renal artery stenosis or renal artery stenosis in a solitary kidney or post-renal transplant 5. current treatment with any antihypertensive agents, whether or not prescribed for this indication, that cannot be safely stopped 6. other conditions or situations that could put potential participants at unacceptable risk due to participation in this study
study to evaluate sti-1499 (covi-guard) in patients with moderate covid-19

Conditions: Covid-19

Summary: randomized, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of sti-1499 (covi-guard™) in hospitalized patients with moderate covid-19

this study is a randomized, double-blind, placebo-controlled study to evaluate the safety, pharmacokinetics and efficacy of a single dose of sti-1499 (covi-guard™), a covid-19 targeting monoclonal antibody, in hospitalized patients with moderate covid-19. four dose levels will be tested: 10 mg, 30 mg, 100 mg, and 200 mg.

Eligibility criteria:
inclusion criteria: * evidence of moderate covid-19, diagnosed standard rt-pcr assay or equivalent testing * willing and able to comply with study procedures and follow-up visits * subject or family member/caregiver must have provided written informed consent which includes signing the institutional review board approved consent form prior to participating in any study related activity. however, if obtaining written informed consent is not possible, other procedures as provided in the march 27th, 2020 fda guidance on conduct of clinical trials of medical products during covid-19 pandemic, question 10, may be used. exclusion criteria: * clinical signs indicative of severe covid-19 * rapidly progressive covid-19 which is likely to progress to "severe" within 24 hours * documented infection other than covid-19 * any medical condition that, in the investigator's opinion, could adversely impact safety * pregnant or lactating women * has participated, or is participating, in a clinical research study evaluating covid-19 convalescent plasma, monoclonal antibodies (mabs) against sars-cov-2, or intravenous immunoglobulin (ivig) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit. note: participants who have been prescribed hydroxychloroquine or chloroquine with or without azithromycin or other approved products for the off-label treatment of covid-19 prior to study enrollment may be included and may continue to receive these agents so long as the dose remains stable. additionally, any approved or authorized treatment (e.g., remdesivir, dexamethasone or treatments approved under an emergency use authorization) is allowed.
qst, blink reflex and nociceptive flexion reflex in headache

Conditions: Head Pain

Summary: the aim of this study is to compare central and peripheric sensitization in headache patients at baseline (t0) and 1 month after (t1) a treatment with an anti-cgrp (fremanezumab-ajovy).

20 patients and 20 healthy subjects will be enrolled. the headache patients will be recruited just before starting their treatment and 1 month after (corresponding to the efficacy peak). hot and cold stimulations will be delivered with the ats probe from the medoc pathway on the forehead and on the hand (palmar face) to determine painful threshold to warm/cold stimuli. a blink reflex will be generated with a concentric electrode placed over the eyebrow and with active/earth electrodes linked to the emg machine for the recording. for the nociceptive flexion reflex, a cutaneous stimulation will be applied on the arm and the response recorded on the corresponding muscles.

Eligibility criteria:
inclusion criteria: patients with headache which are about to receive a treatment with fremanezumab exclusion criteria: * medication changes 1 month prior to the test * neuropathy * acute or chronic pain * medications having effects on the central nervous system * other disease

Keywords: headache fremanezumab blink reflex nociceptive flexion reflex quantitative sensory testing
optimisation of mechanical insufflation:exsufflation

Conditions: Neuromuscular Diseases

Summary: patients with neuromuscular diseases (nmd) can suffer from a range of respiratory problems due to respiratory muscle weakness. cough muscle weakness means secretion clearance from the airways can be problematic, a source of infection, and importantly a cause of death, in this patient group. therefore, these patients are often supported with devices to aid clearance, such as mechanical insufflation-exsufflation (mie). although evidence supports the use of these devices, the optimal technique or settings on the device are not clear. increasingly, higher pressures are used during mie and recent work has demonstrated that there may be a physiological benefit to this. however, higher pressures increase the risk of causing lung collapse and may cause detriment to blood flow back to the heart, which is important as nmd patients frequently have concurrent heart muscle weakness. further, recent work has demonstrated that higher pressures can cause closure of the throat, which is counter-productive in secretion clearance. the overall aim of this study is to investigate methods to manipulate mie to improve secretion clearance in patients with nmd. the questions it seeks to answer are: (i) how can we maximally improve lung recruitment during inspiration, whilst maintaining patient comfort and lower pressures (ii) what is the smallest pressure difference required in expiration to achieve an improvement in cough (iii) do these proposed changes to mie also cause throat closure (iv) what factors do patients believe contribute to their adherence to mie therapy? patients with slowly progressive or stable neuromuscular diseases will be included in the study. participation will involve two visits to the lane fox respiratory unit, each lasting approximately four hours. patients will be recruited from specialist neuromuscular respiratory clinics by their clinical teams.


Eligibility criteria:
inclusion criteria: * stable or slowly progressive neuromuscular disease * respiratory muscle weakness (fvc \<60%, snip \<60%, sleep disordered breathing) * clinical evidence of respiratory secretions or cough peak expiratory flow \<270 and history of lower respiratory tract infection * documented clinical stability by supervising clinician exclusion criteria: * rapidly progressive neuromuscular disease (such as motor neuron disease) * decompensated respiratory failure (ph \< 7.35) * pregnancy * aged \<18 * change in ventilator settings in preceding 4 weeks * significant physical or psychiatric co-morbidity that would prevent compliance with trial protocol
promoting stress management and engagement in introductory physics courses with mindfulness and relaxation

Conditions: Psychological Stress; Coping Skills; Emotions; Emotion Regulation

Summary: this study tests the impact of mindfulness vs. relaxation training on psychological threat and challenge, emotions/emotion regulation, motivation/engagement, and performance among undergraduates enrolled in introductory physics courses. data used to compare groups will be collected from a variety of sources, including self-report surveys, experience sampling and daily diary assessments, physics learning activities, and academic records.


Eligibility criteria:
inclusion criteria: * at least 18 years of age * current university of pittsburgh undergraduate * enrolled in introductory physics * self-reports psychological threat in physics exclusion criteria: * under 18 years of age * not a current university of pittsburgh undergraduate * not enrolled in introductory physics * does not self-report psychological threat in physics

Keywords: mindfulness physics education psychological challenge and threat engagement motivation relaxation
electro-physiological findings and symptoms severity in superior canal dehiscence

Conditions: Superior Semicircular Canal Dehiscence

Summary: this research aims at assessing the validity of three different electro-physiological tests (vestibular evoked myogenic potentials, wideband tympanometry, electrocochleography) used in the investigation of the symptoms severity in the case of superior semi-circular canal dehiscence syndrome.

superior semi-circular canal dehiscence (scd) syndrome can associate several cochlear and vestibular symptoms. recent systematic reviews identified pulsatile tinnitus, autophony, sound-induced and pressure-induced vertigo as most specific signs of scd. these signs are rarely all present and the symptomatology remains highly variable from a patient to another, with frequent though less evocative symptoms such as dizziness or ear pressure. a surgical treatment may be proposed when the symptoms become significantly incapacitating. unfortunately to date, there is no objective marker of this severity and all surgical decisions rely on the importance of patients' complaints. high resolution computed tomography (hrct) of the temporal bone can confirm the diagnosis. electro-physiological investigations such as vestibular evoked myogenic potentials (vemps) have also been extensively described in the diagnosis of scd but they have been reported as independent from the symptoms severity. wideband tympanometry (wbt) and electrocochleography (ecog) have only been studied in few reports but the latter appears as a promising tool in the assessment of the symptoms because it explores inner ear biomechanics, directly involved in the pathophysiology of this condition.

Eligibility criteria:
inclusion criteria: * confirmed unilateral scd (using specific hrct settings and reconstructions) with or without scd symptoms * if present, scd symptoms should be stable * patients understanding and reading french * affiliated to social security. exclusion criteria: * bilateral confirmed scd * doubtful scd * other otologic or neurotologic condition that might mimick scd symptomatology : middle ear conditions, meniere disease, vestibular migraine

Keywords: superior semi-circular canal dehiscence minor syndrome pulsatile tinnitus autophony tullio phenomenon
application of l-prf in periodontal surgery

Conditions: Periodontal Diseases

Summary: the study will compare the clinical outcomes of the two procedures, open flap debridement (ofd) compared to open flap debridement with leukocyte and platelet-rich fibrin (l-pfr) as well as differences in patient postoperative pain perception.

randomization to one of two standard of care procedures: 1. test group: after gingival flap reflection and debridement of bone and root surfaces l-prf will be applied to the alveolar bone, tooth roots, and gingival flap prior to suturing. 2. control group (standard of care): gingival flap reflection and debridement of bone and root surfaces, followed by suturing of the gingival flaps. the study is a split-mouth design, randomized, prospective clinical trial. the protocol will randomize gingival quadrants in subjects to one of two standard of care procedures ofd or ofd + l-prf. patients needing periodontal surgery to correct periodontal disease will be enrolled. there will be two subject groups in this study. each subject will be randomized to one of the treatments for the first quadrant and the contralateral quadrant will receive the other treatment. no risk is expected from being assigned to either group as both procedures are standard of care, with possible benefit of enhanced wound healing and bone regeneration in the test group. allocation of subjects into test group or control group will be based on numbers drawn from a stack of sealed envelopes.

Eligibility criteria:
inclusion criteria: * patients between age 18 and 89 * patients needing open flap debridement procedures for periodontal disease in one or more teeth in the same arch bilaterally (split mouth) * patients must be nonsmokers, former smokers, or current smokers who smoke \<10 cigarettes per day, by self-report * female patients to include non- pregnant women of child-bearing potential. exclusion criteria: * patients who disclose that they will not be able to cooperate with the follow-up schedule. * patients who are mentally incompetent, prisoners, or pregnant (as obtained via chart review or self-report) * pregnant women or women intending to become pregnant during the study period * smokers who smoke \> 10 cigarettes per day

Keywords: open flap debridement periodontal surgery periodontal wound healing
telephone-based genetic counseling or standard genetic counseling in women at risk of carrying the brca1 or brca2 mutation

Conditions: Breast Cancer

Summary: rationale: genetic counseling may work as well over the telephone as it does in-person. it is not yet known whether genetic counseling by telephone is more effective than standard (in-person) genetic counseling in women at risk of carrying the brca1 or brca2 mutation. purpose: this randomized phase iii trial is studying telephone-based genetic counseling to see how well it works compared to standard (in-person) genetic counseling in women at risk of carrying the brca1 or brca2 mutation.

objectives: primary * compare the impact of telephone genetic counseling (tgc) versus standard genetic counseling (sgc) on utilization of brca1/brca2 testing in women at risk of carrying the brca1/brca2 mutation. * compare the relative efficacy of tgc versus sgc on satisfaction with the counseling process, informed decision making, psychosocial distress, and quality of life. secondary * identify participant characteristics that predict differential response to tgc. * explore the mechanisms by which tgc or sgc impact distress and quality of life. outline: this is a randomized, multicenter study. participants are stratified according to participating site. participants are randomized to 1 of 2 groups. * group 1 (standard genetic counseling): participants undergo an in-person genetic counseling session. participants are then given the option of providing blood for genetic testing at the study site. participants who choose to undergo genetic testing receive their results in-person from their genetic counselor. * group 2 (telephone-based genetic counseling): participants undergo a telephone-based genetic counseling session. participants who choose to undergo genetic testing receive a pre-labeled blood kit in the mail. participants receive their results over the phone from their genetic counselor. after completion of genetic counseling, all participants are followed periodically for 1 year. projected accrual: a total of 600 participants will be accrued for this study.

Eligibility criteria:
disease characteristics: * must have at least 10% chance of carrying the brca1/brca2 gene, as defined by ≥ 1 of the following: * first-degree relative of affected family member with a 50% chance of inheriting a brca1/brca2 mutation * second-degree relative with brca1/brca2 mutation with 25% risk of inheritance (parent deceased) * obligate gene carrier or affected woman * must live within 100 miles of the lombardi comprehensive cancer center * no more than 4 weeks since breast or ovarian cancer diagnosis * no metastatic or inflammatory breast cancer or ovarian cancer * no stage iii breast or ovarian cancer while undergoing concurrent chemotherapy patient characteristics: * no psychiatric illness or cognitive disorder that would preclude informed consent prior concurrent therapy: * no prior genetic counseling or testing for brca1 and/or brca2

Keywords: breast cancer
the effects of fes in a variety of walking conditions in people with ms

Conditions: Multiple Sclerosis

Summary: the aim of this study is to measure the difference in the walking performance when functional electrical stimulation (fes) is on and off in people with ms that present foot drop under different 'real life' conditions, i.e. walking while doing another task that requires your attention and after been physically tired

people with multiple sclerosis (pwms) often experience foot drop, which means that the foot is not adequately lifted from the ground when walking. functional electrical stimulation (fes) is applied to the shin muscles to aid lifting the foot of the ground and reduces the risk of trips and falls. pwms that are users of functional electrical stimulation (fes) report that one of the benefits is that it reduces the mental effort of walking and that as a result less concentration is needed when they walk. motor fatigability, which is the reduced ability of the muscles to produce force or power, also negatively affects the walking performance of pwms. there have been several studies showing the benefits of fes to the walking of pwms, but not while performing two tasks at the same time and experiencing fatigability resembling more daily life conditions. the proposed study aims to investigate the direct orthotic effect of fes (fes on vs off) in three different conditions, which include just walking, walking while performing an attention-demanding task and walking with an attention-demanding task after having completed a fatiguing task. the study design of this research allows the quantification of benefits of the use of fes which have until now only be reported subjectively.

Eligibility criteria:
inclusion criteria: for people with ms: * clinically definite multiple sclerosis according to the revised mcdonald criteria. * people with edss ≤ 5.0. * people with ms who experience foot drop. * able to walk at least 200 meters unassisted, i.e without walking aids. for healthy participants: * not been diagnosed with any neurological disease or have any other condition or injury which will affect walking ability. exclusion criteria: for people with ms: * clinically diagnosed relapse within the last month. * any musculoskeletal impairment that can affect walking ability. * cognitive impairments; with a score in the multiple sclerosis neuropsychological screening questionnaire (msnq) ≤ 75. * depression and anxiety; with a score in hospital anxiety \& depression scale (hads) \> 10.